Skip to main
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs Inc. is positioned favorably within the biotechnology sector, particularly as patient adoption of biologics for inflammatory bowel disease (IBD) has increased significantly—rising from 5% to 16% for ulcerative colitis (UC) and from 22% to 44% for Crohn's disease (CD) between 2007 and 2015. The company's lead program, SL-325, a potentially first-in-class DR3 antagonist antibody, is anticipated to capture a robust market share, bolstered by a highlighting of conservative launch estimates that suggest continued growth in sales. Furthermore, the focus on developing SL-425 and other preclinical DR3-based bispecific antibodies indicates a strong pipeline that could enhance Shattuck Labs's market position within IBD treatment options.

Bears say

Shattuck Labs Inc faces a negative outlook due to substantial uncertainties surrounding the efficacy and safety of its lead programs, which may not meet necessary immunogenicity standards, potentially hindering development and market acceptance. Additionally, the persistent underestimation of market growth and advanced therapy utilization in inflammatory bowel disease (IBD) could impact the company’s commercial projections and overall financial performance. Furthermore, the company's leading programs, SL-325 and SL-425, operate in a complex competitive landscape marked by increasing use of biologics that may result in declining surgery rates, thereby affecting market dynamics and revenue potential.

Shattuck Labs (STTK) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 3 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.